Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib

Anti-Cancer Drugs

Volumn 23, Issue SUPPL. 1, 2012, Pages

  López, Rafael López ^a   Del Muro, Xavier García ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

adjuvant therapy; gastrointestinal stromal tumors; imatinib; localized tumor

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MITOSIS RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; RISK; RUPTURE, SPONTANEOUS;

EID: 84863584841     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283559fab     Document Type: Review

References (22)

1. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J NatlCompr Cancer Network 2010; 8 (Suppl 2):S1-41, quiz S42-44.
2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS,Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
3. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CDM, Fletcher JA. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20:3898-3905.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70-83.
5. Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Mak RG, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112:608-615.
6. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465.
7. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39:1411-1419.
8. Novartis. Gleevec(R) (imatinib mesylate tablets): US prescribing information [online]. Available at: gleevec-tabs.pdf. [Accessed 5 August 2011].
9. European Medicines Agency. Glivec(R): Summary of product characteristics [online]. Available at: document-library/EPAR-Product-Information/human/000406/ WC500022207.pdf [Accessed 5 August 2011].
10. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Burton Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625.
11. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626-632.
12. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002; 347:472-480.
13. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134.
14. Nilsson B, Sjö lund K, Kindblom LG,Meis-Kindblom JM, Bümming P, Nilsson O, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96:1656-1658.
15. Dematteo RP, Owzar K, Antonescu CEA. Efficacy of adjuvant imatinib mesylate following complete resection of localized primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract no. 8], in 2008 Gastrointestinal Cancer Symposium -ASCO2008; 2007; Orlando, FL.
16. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PWT, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebocontrolled trial. Lancet 2009; 373:1097-1104.
17. Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 2010; 28 (Suppl):15s (abstr 10006).
18. Li J, Gong JF, Wu AW, Shen L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011; 37:319-324.
19. Reichardt P, Hartmann JT, Sundby Hall K, Eriksson M, Schütte J, Ramadori G, et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment -the first analysis in the SSGXVIII/ AIO trial patient population. Eur J Cancer 2011; 47 (Suppl 2):1531LBA.
20. Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Reichardt A, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO) [abstr]. J Clin Oncol 2011; 29 (Suppl):LBA1.
21. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl.5):v98-102.
22. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): soft tissue sarcoma. Version 2.2011; 2011. Available at: physician-gls/f-guidelines.asp#site [Accessed 27 January 2011].